{"id":2266,"date":"2025-11-05T09:14:38","date_gmt":"2025-11-05T08:14:38","guid":{"rendered":"https:\/\/semmelweis.hu\/esk\/?p=2266"},"modified":"2025-11-28T11:02:55","modified_gmt":"2025-11-28T10:02:55","slug":"a-covid-19-elleni-vedooltasok-es-a-sulyos-kimenetel-kozotti-osszefuggesek-vizsgalata-a-korhazban-kezelt-covid-19-betegek-koreben-magyarorszagon-az-omikron-varians-elotti-idoszakban","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/esk\/2025\/11\/05\/a-covid-19-elleni-vedooltasok-es-a-sulyos-kimenetel-kozotti-osszefuggesek-vizsgalata-a-korhazban-kezelt-covid-19-betegek-koreben-magyarorszagon-az-omikron-varians-elotti-idoszakban\/","title":{"rendered":"A COVID-19 elleni v\u00e9d\u0151olt\u00e1sok \u00e9s a s\u00falyos kimenetel k\u00f6z\u00f6tti \u00f6sszef\u00fcgg\u00e9sek vizsg\u00e1lata a k\u00f3rh\u00e1zban kezelt COVID-19-betegek k\u00f6r\u00e9ben Magyarorsz\u00e1gon, az Omikron vari\u00e1ns el\u0151tti id\u0151szakban"},"content":{"rendered":"

Sz\u00e1mos tanulm\u00e1ny vizsg\u00e1lta, hogy a COVID-19 elleni v\u00e9d\u0151olt\u00e1sok mik\u00e9nt seg\u00edtenek megel\u0151zni a k\u00f3rh\u00e1zi kezel\u00e9st ig\u00e9nyl\u0151 megbeteged\u00e9st, ugyanakkor tov\u00e1bbra is kev\u00e9s az ismeret\u00fcnk a betegs\u00e9g s\u00falyos kimeneteleir\u0151l \u00e9s arr\u00f3l, hogy az olt\u00e1sok milyen m\u00e9rt\u00e9k\u0171 v\u00e9delmet ny\u00fajtanak a megbeteged\u00e9sek s\u00falyos lefoly\u00e1s\u00e1val szemben.<\/p>\n

Jelen, retrospekt\u00edv tanulm\u00e1nyunkban a pand\u00e9mia kezdet\u00e9t\u0151l az Omikron vari\u00e1ns megjelen\u00e9s\u00e9ig tart\u00f3 id\u0151szak alatt (2020. m\u00e1rcius – 2021. december 31. k\u00f6z\u00f6tt \u2013 a vuhani t\u00f6rzs, Alfa-, ill. Delta-vari\u00e1ns dominanci\u00e1j\u00e1nak id\u0151szak\u00e1ban) a Semmelweis Egyetem fekv\u0151beteg-ell\u00e1t\u00f3 egys\u00e9g\u00e9ben megjelent p\u00e1cienseket vizsg\u00e1ltuk, akiknek RT-PCR m\u00f3dszerrel igazolt a SARS-CoV-2 fert\u0151z\u00e9s\u00fck volt \u00e9s a COVID-19 miatt kezel\u00e9sben r\u00e9szes\u00fcltek. A betegeket BNO-k\u00f3dok alapj\u00e1n azonos\u00edtottuk, kieg\u00e9sz\u00edtve a NEAK-t\u00f3l sz\u00e1rmaz\u00f3 k\u00f3rel\u0151zm\u00e9nyre (kr\u00f3nikus alapbetegs\u00e9gek) vonatkoz\u00f3 inform\u00e1ci\u00f3kkal. A betegeket a k\u00f3rh\u00e1zi kezel\u00e9sb\u0151l val\u00f3 elbocs\u00e1t\u00e1sukig vagy a k\u00f3rh\u00e1zban bek\u00f6vetkezett hal\u00e1lukig k\u00f6vett\u00fck nyomon. A betegeket olt\u00e1si st\u00e1tusz szerint h\u00e1rom k\u00fcl\u00f6nb\u00f6z\u0151 kateg\u00f3ri\u00e1ba soroltuk \u00e9s csoportonk\u00e9nt \u00f6sszehason\u00edtottuk:<\/p>\n

    \n
  1. oltatlanok (84,8 %)<\/li>\n
  2. befejezett alapimmuniz\u00e1l\u00e1sban r\u00e9szes\u00fcltek (13,4 %)<\/li>\n
  3. alapimmuniz\u00e1l\u00e1sban r\u00e9szes\u00fcltek \u00e9s legal\u00e1bb 14 nappal a k\u00f3rh\u00e1zi felv\u00e9telt megel\u0151z\u0151en megkapt\u00e1k az eml\u00e9keztet\u0151 olt\u00e1st (1,8 %)<\/li>\n<\/ol>\n

    Az elemz\u00e9st statisztikai m\u00f3dszerekkel v\u00e9gezt\u00fck, \u00e9letkorra, nemre \u00e9s a t\u00e1rsbetegs\u00e9gekre korrig\u00e1lva. Els\u0151dleges v\u00e9gpont<\/em>k\u00e9nt kiz\u00e1r\u00f3lag az egyes betegek legs\u00falyosabb kimenetel\u00e9t vett\u00fck figyelembe (pl. oxig\u00e9nter\u00e1pia, vagy k\u00fcl\u00f6nb\u00f6z\u0151 l\u00e9legeztet\u00e9si t\u00edpusok, vagy ECMO illetve k\u00f3rh\u00e1zi hal\u00e1loz\u00e1s). Emellett az els\u0151dleges kimenetel egyes l\u00e9pcs\u0151fokait, melyeken \u00e1t a betegek eljutottak a legs\u00falyosabbig (pl. az oxig\u00e9nter\u00e1pi\u00e1n, nem-invaz\u00edv ill. invaz\u00edv l\u00e9legeztet\u00e9sen, ECMO-n \u00e1t a k\u00f3rh\u00e1zban bek\u00f6vetkezett hal\u00e1lig) kulcsfontoss\u00e1g\u00fa, k\u00fcl\u00f6n\u00e1ll\u00f3 m\u00e1sodlagos kimenetelek<\/em>k\u00e9nt is meghat\u00e1roztuk, \u00e9s ezeket k\u00fcl\u00f6n-k\u00fcl\u00f6n m\u00e1sodlagos v\u00e9gpont<\/em>k\u00e9nt is \u00e9rt\u00e9kelt\u00fck, ekkor ugyanaz a beteg t\u00f6bb kateg\u00f3ri\u00e1ban is szerepelhetett. \u00d6sszesen 7 575 beteget v\u00e1logattunk be az elemz\u00e9sbe, \u00e9s ezek t\u00f6bb mint fel\u00e9n\u00e9l (56% – 4256 f\u0151) siker\u00fclt azonos\u00edtani egy, az adott betegn\u00e9l legs\u00falyosabbk\u00e9nt defini\u00e1lt, \u00f6sszetett els\u0151dleges kimenetel b\u00e1rmelyik \u00f6sszetev\u0151, m\u00e1sodlagos kimenetel\u00e9t.<\/p>\n

    Az 1. t\u00e1bl\u00e1zatban szerepl\u0151 eredm\u00e9nyek az \u00f6sszes kimenetelre, teh\u00e1t a m\u00e1sodlagos v\u00e9gpontokra vonatkoznak: ennek alapj\u00e1n a Covid-19 elleni v\u00e9d\u0151olt\u00e1sok az oltott szem\u00e9lyek k\u00f6r\u00e9ben szignifik\u00e1nsan, mintegy fel\u00e9re cs\u00f6kkentett\u00e9k az invaz\u00edv l\u00e9legeztet\u00e9s (OR: 0,52; 95% CI: 0,38\u20130,71), \u00e9s kb. 45%-kal (OR: 0,55; 95% CI: 0,46\u20130,67) a k\u00f3rh\u00e1zi hal\u00e1loz\u00e1s es\u00e9ly\u00e9t az oltatlan szem\u00e9lyekhez k\u00e9pest. A k\u00f3rh\u00e1zi felv\u00e9telt megel\u0151z\u0151 6 h\u00f3napon bel\u00fcl adott meger\u0151s\u00edt\u0151 olt\u00e1ssal szint\u00e9n minden s\u00falyos kimenetel es\u00e9lye cs\u00f6kkent az oltatlanokhoz viszony\u00edtva.<\/p>\n

      \n
    1. T\u00e1bl\u00e1zat: A COVID-19 elleni oltotts\u00e1gi st\u00e1tusz \u00e9s minden egyes kimenetel (m\u00e1sodlagos v\u00e9gpont) k\u00f6z\u00f6tti \u00f6sszef\u00fcgg\u00e9s es\u00e9lye kimenetelenk\u00e9nt; korrig\u00e1lva az \u00e9letkorra, nemre, 2-es t\u00edpus\u00fa diab\u00e9teszre, kardiovaszkul\u00e1ris betegs\u00e9gekre, COPD-re \u00e9s rosszindulat\u00fa daganatokra (logisztikus regresszi\u00f3s modellek alapj\u00e1n)<\/strong><\/li>\n<\/ol>\n\n\n\n\n\n\n\n\n\n
      \n

      Vizsg\u00e1lt m\u00e1sodlagos v\u00e9gpontok<\/strong><\/p>\n<\/td>\n

      		\n

      Oltatlan<\/strong><\/p>\n<\/td>\n

      		\n

      Alapimmuniz\u00e1lt COVID-19 ellen<\/strong><\/p>\n<\/td>\n

      		\n

      Eml\u00e9keztet\u0151 COVID-19 elleni olt\u00e1sban r\u00e9szes\u00fclt<\/strong><\/p>\n<\/td>\n<\/tr>\n

      \n

       <\/p>\n<\/td>\n

      		\n

       <\/p>\n<\/td>\n

      		\n

      Es\u00e9lyh\u00e1nyados (OR) \u00e9s 95% CI<\/strong><\/p>\n<\/td>\n<\/tr>\n

      \n

      Oxig\u00e9nter\u00e1pia<\/p>\n<\/td>\n

      		\n

      Referencia<\/p>\n<\/td>\n

      		\n

      1.00 (0.87; 1.14)<\/p>\n<\/td>\n

      		\n

      0.76 (0.54; 1.08)<\/p>\n<\/td>\n<\/tr>\n

      \n

      Non-invaz\u00edv l\u00e9legeztet\u00e9s<\/p>\n<\/td>\n

      		\n

      1.00 (0.74; 1.33)<\/p>\n<\/td>\n

      		\n

      0.72 (0.31;1.64)<\/p>\n<\/td>\n<\/tr>\n

      \n

      Invaz\u00edv l\u00e9legeztet\u00e9s<\/p>\n<\/td>\n

      		\n

      0.52 (0.38; 0.71)<\/strong><\/p>\n<\/td>\n

      		\n

      0.24 (0.08; 0.76)<\/strong><\/p>\n<\/td>\n<\/tr>\n

      \n

      ECMO<\/p>\n<\/td>\n

      		\n

      0.54 (0.17; 1.76)<\/p>\n<\/td>\n

      		\n

      –<\/p>\n<\/td>\n<\/tr>\n

      \n

      Hal\u00e1l<\/p>\n<\/td>\n

      		\n

      0.55 (0.46; 0.67)<\/strong><\/p>\n<\/td>\n

      		\n

      0.61 (0.41; 0.92)<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

      95% CI: 95% Konfidencia intervallum, ECMO: extrakorpor\u00e1lis membr\u00e1noxigeniz\u00e1ci\u00f3
      \n<\/span>Forr\u00e1s: Virus Res. 2025 Sep 18;361:199633. doi:\u00a010.1016\/j.virusres.2025.199633<\/a> publik\u00e1ci\u00f3 4. t\u00e1bl\u00e1zata alapj\u00e1n SE ESK saj\u00e1t szerkeszt\u00e9s<\/span><\/p>\n

      Ha kiz\u00e1r\u00f3lag a legs\u00falyosabb kimeneteleket (els\u0151dleges v\u00e9gpontok) vett\u00fck figyelembe (2. t\u00e1bl\u00e1zat), a 12 h\u00f3napon bel\u00fcl adott alapimmuniz\u00e1l\u00e1s k\u00f6zel fel\u00e9re cs\u00f6kkentette (RRR=0.52; 95 % CI: 0.30-0.89) az invaz\u00edv l\u00e9legeztet\u00e9s \u00e9s a hal\u00e1loz\u00e1s kock\u00e1zat\u00e1t (RRR: 0.50, 95 % CI: 0.41-0.61) az oltatlanokhoz k\u00e9pest, m\u00edg a 6 h\u00f3napon bel\u00fcl adott eml\u00e9keztet\u0151 olt\u00e1s \u00f6sszesen 54%-kal cs\u00f6kkentette a k\u00f3rh\u00e1zi hal\u00e1loz\u00e1s kock\u00e1zat\u00e1t az oltatlan csoporthoz k\u00e9pest (RRR=0,46, 95% CI:0,30-0,72).<\/p>\n

        \n
      1. T\u00e1bl\u00e1zat: A legs\u00falyosabb kimenetel (els\u0151dleges v\u00e9gpont*) kialakul\u00e1sa \u00e9s a COVID-19 elleni oltotts\u00e1gi st\u00e1tusz k\u00f6z\u00f6tti \u00f6sszef\u00fcgg\u00e9s; korrig\u00e1lva az \u00e9letkorra, nemre, 2-es t\u00edpus\u00fa diab\u00e9teszre, kardiovaszkul\u00e1ris betegs\u00e9gekre, COPD-re \u00e9s rosszindulat\u00fa daganatokra, a nem oltott betegcsoportot referenciak\u00e9nt tekintve (politom logisztikus regresszi\u00f3s modell becsl\u00e9se alapj\u00e1n)<\/strong><\/li>\n<\/ol>\n\n\n\n\n\n\n\n\n
        \n

        Vizsg\u00e1lt els\u0151dleges v\u00e9gpont<\/strong><\/p>\n<\/td>\n

        		\n

        Alapimmuniz\u00e1lt COVID-19 ellen<\/strong><\/p>\n<\/td>\n

        		\n

        Eml\u00e9keztet\u0151 COVID-19 elleni olt\u00e1sban r\u00e9szes\u00fclt<\/strong><\/p>\n<\/td>\n<\/tr>\n

        \n

         <\/p>\n<\/td>\n

        		\n

        Relat\u00edv kock\u00e1zati ar\u00e1ny (RRR)\u2020<\/sup> \u00e9s 95% CI<\/strong><\/p>\n<\/td>\n<\/tr>\n

        \n

        Oxig\u00e9nter\u00e1pia<\/p>\n<\/td>\n

        		\n

        0.84 (0.71; 0.98)<\/strong><\/p>\n<\/td>\n

        		\n

        0.57 (0.37; 0.88)<\/strong><\/p>\n<\/td>\n<\/tr>\n

        \n

        Non-invaz\u00edv l\u00e9legeztet\u00e9s<\/p>\n<\/td>\n

        		\n

        0.79 (0.56; 1.35)<\/p>\n<\/td>\n

        		\n

        0.48 (0.12; 2.01)<\/p>\n<\/td>\n<\/tr>\n

        \n

        Invaz\u00edv l\u00e9legeztet\u00e9s<\/p>\n<\/td>\n

        		\n

        0.52 (0.30; 0.89)<\/strong><\/p>\n<\/td>\n

        		\n

        0.70 (0.21; 2.27)<\/p>\n<\/td>\n<\/tr>\n

        \n

        Hal\u00e1l<\/p>\n<\/td>\n

        		\n

        0.50 (0.41; 0.61)<\/strong><\/p>\n<\/td>\n

        		\n

        0.46 (0.30; 0.72)<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

        95% CI: 95%-os konfidencia-intervallum, ECMO: extrakorpor\u00e1lis membr\u00e1noxigeniz\u00e1ci\u00f3
        \n<\/span>* Minden beteget abba a kimenetelbe soroltuk, amely a sz\u00e1mukra a legs\u00falyosabb volt.
        \n<\/em><\/span>\u2020 Az oltatlanokhoz k\u00e9pest. (Pl. P\u00e9ld\u00e1ul a 0,50-es relat\u00edv kock\u00e1zati ar\u00e1ny az oltott betegekn\u00e9l azt jelenti, hogy az oltottak eset\u00e9ben a hal\u00e1loz\u00e1s relat\u00edv kock\u00e1zata (a l\u00e9legeztet\u00e9st nem ig\u00e9nyl\u0151, teh\u00e1t legkedvez\u0151bb kimenetel\u0171 \u00e1llapothoz viszony\u00edtva) osztva a nem oltott betegekn\u00e9l ugyan\u00edgy sz\u00e1m\u00edtott relat\u00edv kock\u00e1zattal.
        \n<\/em><\/span>Forr\u00e1s: Virus Res. 2025 Sep 18;361:199633. doi:\u00a010.1016\/j.virusres.2025.199633<\/a> publik\u00e1ci\u00f3 5. t\u00e1bl\u00e1zata alapj\u00e1n SE ESK saj\u00e1t szerkeszt\u00e9s<\/span><\/p>\n

        \u00d6sszess\u00e9g\u00e9ben elmondhat\u00f3, hogy az Omikron megjelen\u00e9se el\u0151tti id\u0151szakban a k\u00f3rh\u00e1zban kezelt COVID-19-betegek k\u00f6r\u00e9ben mind az alapimmuniz\u00e1l\u00e1s, mind az eml\u00e9keztet\u0151 olt\u00e1sok jelent\u0151sen cs\u00f6kkentett\u00e9k egyes s\u00falyos kimenetelek \u00e9s a k\u00f3rh\u00e1zi hal\u00e1loz\u00e1s kock\u00e1zat\u00e1t.<\/p>\n

        Association between COVID-19 vaccination and progression to severe outcomes in hospitalized COVID-19 patients in Hungary during the pre-Omicron era of the COVID-19 pandemic<\/strong><\/h3>\n

        Zolt\u00e1n Vok\u00f3<\/em>1,2,3<\/sup>, Gerg\u0151 T\u00fari<\/em>4,5<\/sup>, Beatrix Oroszi<\/em>4,5<\/sup>, \u00c9va Belicza6,7<\/sup>, Tam\u00e1s Kov\u00e1ts6,7<\/sup>, Veronika M\u00fcller7<\/sup>, J\u00e1nos R\u00e9thelyi8<\/sup>, Attila Szij\u00e1rt\u00f39<\/sup>, Tam\u00e1s Masszi10<\/sup>, Istv\u00e1n Tak\u00e1cs10<\/sup>, J\u00e1nos G\u00e1l11<\/sup>, Zsolt G\u00f6b\u00f6l12<\/sup>, Attila Szab\u00f313<\/sup>, Csaba Varga14<\/sup>, D\u00e1vid Becker15<\/sup>, B\u00e9la Merkely15<\/sup><\/p>\n

        1<\/sup>\u00a0 Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary
        \n2<\/sup>\u00a0 Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest, Hungary
        \n3<\/sup>\u00a0 Syreon Research Institute, Budapest, Hungary
        \n4<\/sup>\u00a0 National Laboratory for Health Security, Epidemiology and Surveillance Centre Semmelweis University, Budapest, Hungary
        \n5<\/sup>\u00a0 Doctoral School of Health Sciences, University of Debrecen, Debrecen, Hungary
        \n6<\/sup>\u00a0 Data-Driven Health Division of National Laboratory for Health Security, Health Services Management Training Centre, Semmelweis University, Budapest, Hungary
        \n7<\/sup>\u00a0 Department of Pulmonology, Semmelweis University, Budapest, Hungary
        \n8<\/sup>\u00a0 Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
        \n9<\/sup>\u00a0 Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, Budapest, Hungary
        \n10<\/sup> Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary
        \n11<\/sup> Department of Anesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary
        \n12<\/sup> Multidisciplinary Day Surgery Clinic, Semmelweis University, Budapest, Hungary
        \n13<\/sup> Pediatric Center, Semmelweis University, Budapest, Hungary
        \n14<\/sup> Department of Emergency Medicine, Semmelweis University, Budapest, Hungary
        \n15<\/sup> Heart and Vascular Center of Semmelweis University, Budapest, Hungary<\/p>\n

        Abstract<\/strong><\/h5>\n

        COVID-19 vaccines reduce hospitalization risk, but data on severe outcomes are limited. We analyzed the impact of COVID-19 vaccination on severe outcomes in hospitalized patients in Hungary during the pre-Omicron era, addressing a regional knowledge gap. This retrospective study included hospitalized patients with PCR-confirmed COVID-19 (March 2020 – December 2021) who were categorized as unvaccinated, primary immunized, or booster-vaccinated. Outcomes included oxygen therapy, ventilation types, ECMO, and death, with the most severe outcome as the primary outcome and individual outcomes as secondary measures. Polytomous logistic regression calculated relative risk ratios for the primary outcome and COVID-19 vaccination status, while logistic regression estimated odds ratios for individual outcomes. During the study, 7575 patients were hospitalized with PCR-confirmed COVID-19: 6420 (84.8 %) were unvaccinated, 1016 (13.4 %) received a primary vaccination series, and 139 (1.8 %) had received a booster dose. COVID-19 vaccination reduced the risk of both invasive ventilation and in-hospital death as the most severe outcome by 50 % within 12 months (relative risk ratio [RRR]: 0.52, 95 % CI: 0.30-0.89; 0.50, 95 % CI: 0.41-0.61). Booster doses within six months decreased the risk of in-hospital death to a similar extent (RRR 0.46, 95 % CI: 0.30-0.72). Primary and booster vaccination reduced the risk of progression to severe outcomes in hospitalized COVID-19 patients.<\/p>\n

        Vok\u00f3 Z, T\u00fari G, Oroszi B, Belicza \u00c9, Kov\u00e1ts T, M\u00fcller V, R\u00e9thelyi J, Szij\u00e1rt\u00f3 A, Masszi T, Tak\u00e1cs I, G\u00e1l J, G\u00f6b\u00f6l Z, Szab\u00f3 A, Varga C, Becker D, Merkely B. Association between COVID-19 vaccination and progression to severe outcomes in hospitalized COVID-19 patients in Hungary during the pre-Omicron era of the COVID-19 pandemic. Virus Res. 2025 Sep 18;361:199633. doi: 10.1016\/j.virusres.2025.199633. Epub ahead of print. PMID: 40975400; PMCID: PMC12494597.<\/span><\/p>\n

        https:\/\/www.sciencedirect.com\/science\/article\/pii\/S016817022500111X\u00a0<\/strong><\/a><\/p>\n

        K\u00e9sz\u00edtette az \"\"\u00a0<\/em><\/span><\/p>\n

        \"\"<\/em>RRF-2.3.1-21-2022-00006\u00a0<\/span><\/span><\/p>\n

        \"\"<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

        Sz\u00e1mos tanulm\u00e1ny vizsg\u00e1lta, hogy a COVID-19 elleni v\u00e9d\u0151olt\u00e1sok mik\u00e9nt seg\u00edtenek megel\u0151zni a k\u00f3rh\u00e1zi kezel\u00e9st ig\u00e9nyl\u0151 megbeteged\u00e9st, ugyanakkor tov\u00e1bbra is kev\u00e9s az ismeret\u00fcnk a betegs\u00e9g s\u00falyos kimeneteleir\u0151l \u00e9s arr\u00f3l, hogy az olt\u00e1sok milyen m\u00e9rt\u00e9k\u0171 v\u00e9delmet ny\u00fajtanak a megbeteged\u00e9sek s\u00falyos lefoly\u00e1s\u00e1val szemben. Jelen, retrospekt\u00edv tanulm\u00e1nyunkban a pand\u00e9mia kezdet\u00e9t\u0151l az Omikron vari\u00e1ns megjelen\u00e9s\u00e9ig tart\u00f3 id\u0151szak alatt (2020. m\u00e1rcius …<\/p>\n","protected":false},"author":102284,"featured_media":2267,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-2266","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cikk-osszefoglalok"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/users\/102284"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/comments?post=2266"}],"version-history":[{"count":3,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2266\/revisions"}],"predecessor-version":[{"id":2319,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2266\/revisions\/2319"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media\/2267"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media?parent=2266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/categories?post=2266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/tags?post=2266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}